止吐注射 (antiemetics IV) Chemotherapy-induced nausea and vomiting; Prophylaxis.
Postoperative nausea and vomiting.
Postoperative nausea and vomiting; Prophylaxis.
Radiation-induced nausea and vomiting; Prophylaxis.

Granisetron hydrochloride is a selective antagonist of 5-hydroxytryptamine(3) (5-HT(3)) receptors present peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone. Binding results in blockade of serotonin stimulation and subsequent vomiting triggered by emetogenic stimuli. Granisetron hydrochloride has little or no affinity for other serotonin receptors, for adrenergic, for dopamine-D(2), histamine-H(1), benzodiazepine, picrotoxin or opioid receptors.

Distribution: Vd: (IV, cancer patients), 3.07 L/kg
Vd: (IV, 21 y to 42 y), 3.04 L/kg
Vd: (IV, 65 y to 81 y), 3.97 L/kg
Vd: (IV, adult postoperative patients), 2.42 L/kg
Metabolism:
Hepatic; extensive; P450 CYP3A; N-demethylation, oxidation followed by conjugation
Excretion:
Renal: (IV), 49% as metabolites, approximately 12% unchanged. Elimination Half Life: Cancer patients: (IV), 8.95 h 21 y to 42 y: (IV), 4.91 h; 65 y to 81 y: (IV), 7.69 h Adult postoperative patients: (IV), 8.63 h

Hypersensitivity to granisetron or any of its components

Fetal risk cannot be ruled out. (TH)

Infant risk cannot be ruled out.(MDX)

Common:
Neurologic: Asthenia (oral, 14% to 18% ), Headache (8.6% to 21% ), Somnolence (up to 10% )
Other: Fever (3% to 56% )
Serious:
Cardiovascular: Prolonged QT interval
Immunologic: Hypersensitivity reaction

Chemotherapy-induced nausea and vomiting; Prophylaxis
Postoperative nausea and vomiting
1 mg IV
Postoperative nausea and vomiting; Prophylaxis
1 mg IV before induction of anesthesia or immediately before reversal of anesthesia

Chemotherapy-induced nausea and vomiting; Prophylaxis:
2 years and older, 10 mcg/kg IV 30 minutes before chemotherapy

no dosage adjustment necessary

no dosage adjustment necessary